
Mycenax Biotech is a contract development and manufacturing organization serving biopharmaceutical companies with drug development and production services.
mycenax.comCrawled Nov 7, 2026
The company offers contract development and manufacturing services using a PIC/S GMP-certified facility and an advanced research and development team.
Mycenax collaborates with global partners to accelerate research and development (R&D) and market introduction of advanced antibody-drug conjugates (ADCs). The company hosted the 2026 Emerging Biologics Summit Asia, where industry leaders discussed challenges in ADC development and production. These partnerships aim to streamline innovation in biologic therapies.
Sep 2026GeneOnline News -News article
Cytiva collaborates with Mycenax Biotech to develop AI-driven solutions for downstream bioprocessing. The partnership aims to create advanced, scalable technologies for biomanufacturing workflows. Key figures include Jeff Wang, Cytiva’s Business Head for Taiwan, and Dr. Pei-Jiun Chen, CEO and President of Mycenax Biotech.
Aug 2026GeneOnline News -News article
Mycenax Biotech and SPERA PHARMA have partnered to improve antibody-drug conjugate (ADC) manufacturing. The alliance aims to streamline production processes for next-generation cancer therapies. Both companies specialize in biopharmaceutical development, combining expertise to accelerate ADC-based drug delivery solutions.
Sep 2025GeneOnline News -News article
Mycenax Biotech partners with SPERA PHARMA, a Japan-based contract development and manufacturing organization (CDMO), to accelerate antibody-drug conjugate (ADC) development. The alliance focuses on leveraging SPERA PHARMA’s expertise in manufacturing to support Mycenax’s pipeline. Both companies aim to streamline ADC production processes for potential therapeutic advancements.
Sep 2025PharmaSourceNews article